Clinical Trials

 
For further information on any of the following clinical trials, please contact Ann Marie Lavorna , RN our clinical research coordinator at 631.444.1131 . 
 
  •  Case-Crossover Study of PDE5 Inhibitor Exposure as a Potential "Trigger Factor" for Acute NAION; Pfizer

This is a study that involves patients with ischemic optic neuropathy and role that certain medications play in the genesis of this vision loss. 

  •  A Multicenter, Double-blind, Randomized, Placebo controlled Study of Weight-Reduction and/or Low-Sodium Diet plus Acetazolamide vs Diet plus Placebo in Subjects with Idiopathic Intracranial Hypertension with Mild Visual Loss (IIHTT)
An investigation, sponsored by the National Eye Institute on the treatment and pathogenesis of Idiopathic Intracranial Hypertension (Pseudtumor Cerebri). The study compares the effects of diet alone versus Diet + Diamox. 
 
  •  Age-Related Eye Disease Study 2 (AREDS2): A Multi-center, Randomized Trial of Lutein, Zeaxanthin, and Omega-3 Long-Chain Polyunsaturated Fatty Acids (Docosahexaenoic Acid [DHA] and Eicosapentaenoic Acid [EPA]) in Age-Related Macular Degeneration (AREDS II)

The Age-Related Eye Disease Study 2 (AREDS2) is a multi-center, randomized trial designed to assess the effects of oral nutritional supplements (macular xanthophylls (lutein and zeaxanthin) and/or long-chain omega-3 fatty acids (docosahexaenoic acid) [DHA] and eicosapentaenoic acid [EPA] ) on the progression to advanced age-related macular degeneration (AMD).  An additional goal of the study is to assess whether forms of the AREDS nutritional supplement with reduced zinc and/or no beta-carotene works as well as the original supplement in reducing the risk of progression to advanced AMD.
 

 

  •  Maestro-03A: A Double Blind Placebo Controlled Multicenter Study to Evaluate the Effect of MBP8298 in Visual Function Testing and Optical Coherence Tomography in Subjects with Secondary Progressive MS
  • CONSCIOUS-3 : Clazosentan to Overcome Neurological Ischemia and Infarct Occurring after aneurysmal Subarachnoid hemorrhage. A prospective, multi-center, double-blind, randomized, placebo-controlled, parallel-group study to assess the efficacy and safety of clazosentan in reducing vasospasm-related morbidity and all-cause mortality in adult patients with aneurysmal subarachnoid hemorrhage treated by endovascular coiling. AC-054-302
  •  CONSCIOUS-2: Clazosentan to Overcome Neurological Ischemia and Infarct Occurring after Subarachnoid hemorrhage.
  •  Pediatric MS Center
  •  Actelion ACT-128800 RRMS: Multicenter, randomized, double-blind, placebo-controlled, parallel-group, dose-finding study to evaluate the efficacy, safety, and tolerability of three doses of ACT-128800, an oral S1P1 receptor agonist, administered for twenty-four weeks in patients with relapsing-remitting multiple sclerosis; Protocol AC-058B201
  • PUFS: Pipeline for Uncoilable or Failed Aneurysms. #CLP-0005
  • CFTY720D2306 - A double-blind, randomized, multicenter, placebo-controlled, parallel-group study comparing the efficacy and safety of 1.25mg FTY720 administered orally once daily versus placebo in patients with primary progressive multiple sclerosis



Last updated by psibony on May 22, 2011

© 2012 Stony Brook Medicine
http://www.stonybrookmedicine.edu/
101 Nicolls Road Stony Brook, NY 11794
631-689-8333

For technical questions, contact the Webmaster.